晚期前列腺癌黑人男性全身治疗差异:我们处于何种境地?
本综述回顾真实世界登记数据与前瞻性临床试验,重点关注平等可及医疗环境下黑人男性与白人男性转移性前列腺癌全身治疗的结局差异。结果显示,在有标准化医疗供给与随访的前瞻性研究及临床试验中,黑人男性接受全身治疗的结局可能与白人男性相似甚至更好。作者指出种族差异的非生物学驱动因素,强调减少医疗可及与供给障碍及纳入临床试验对解决差异至关重要。
要点
- 在有标准化医疗与随访的前瞻性研究及临床试验中,黑人男性转移性前列腺癌全身治疗结局可能与白人男性相似甚至更好
- 真实世界登记数据显示黑人男性前列腺癌存在多层面差异,与较白人男性更差的生存结局相关
- 作者强调减少医疗可及与供给障碍并纳入临床试验对解决全身治疗结局差异至关重要
核心结论
- 在有标准化医疗供给与随访的前瞻性研究及临床试验中,黑人男性转移性前列腺癌全身治疗结局可能与白人男性相似甚至更好。
- 作者指出种族差异存在非生物学驱动因素,减少医疗可及与供给障碍及纳入临床试验对解决全身治疗结局差异至关重要。
研究设计与样本
- 综述:回顾真实世界登记数据与前瞻性临床试验,重点关注医疗平等可及环境,比较黑人与白人男性转移性前列腺癌全身治疗结局。
- 原文未报告纳入研究数量、检索数据库或检索时间范围。
主要发现
- 真实世界登记数据中黑人男性前列腺癌存在多层面差异,与较白人男性更差的生存结局相关。
- 在医疗供给与随访更可能标准化的前瞻性研究及临床试验中,黑人男性全身治疗结局可能与白人男性相似甚至更好。
临床怎么用
- 作者认为减少医疗可及与供给障碍并纳入临床试验对解决黑人男性转移性前列腺癌全身治疗结局差异至关重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate cancer represents the most common cancer diagnosis in Black men and is the second leading cause of cancer death in this population. Multilevel disparities have been well-documented in Black men with prostate cancer and play a role in poorer survival outcomes when compared with White men with prostate cancer. In this review, we highlight the changing trend in disparities for systemic therapy outcomes in Black men diagnosed with metastatic prostate cancer. METHODS: We reviewed data from real-world registries and prospective clinical trials with a particular focus on equal access settings to compare outcomes to systemic therapies between Black and White men with metastatic prostate cancer. RESULTS: In metastatic prostate cancer, there is growing evidence to suggest that Black men may have similar, if not better, outcomes to systemic therapies than White men with advanced disease, as corroborated by prospective studies and clinical trials where health care delivery and follow-up are more likely to be standardized. CONCLUSION: This review illustrates the importance of nonbiological drivers of racial disparities in Black men with advanced prostate cancer. Mitigating barriers to health care access and delivery as well as including participation in clinical trials will be pivotal to ongoing efforts to address disparities in systemic therapy outcomes for Black men with metastatic prostate cancer.
引用
- Gong J, Kim DM, De Hoedt AM, et al. Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand? J Clin Oncol. 2023. PMID: 37890125. doi:10.1200/JCO.23.00949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。